AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lymphoma
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Patients must have LBCL histologically confirmed
    2. 2) Patients must have relapsed or refractory disease after their last therapy
    3. 3) A tumor tissue sample (formalin-fixed paraffin-embedded tissue block or sectioned tissue), along with a corresponding local pathology report, must be available for submission to the Sponsor

You may not be eligible for this study if the following are true:

    1. 1) Patients who have a history of malignancy other than the lymphoma
    2. 2) Patients with active fungal, bacterial, viral, or other infection that requires intravenous antimicrobials
    3. 3) Patients who received prior allogeneic stem cell or any other organ transplant



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.